Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Warns of Inadvertent Xocova Use in Pregnant Women after 2 Cases Reported
January 25, 2023
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- PM Kishida Hails Lecanemab as World’s First Innovative AD Drug Originating from Japan
January 24, 2023
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
January 24, 2023
- Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
- Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
- First Abortion Pill Candidate in Japan Up for Panel Review on Jan. 27
January 23, 2023
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
January 23, 2023
- PMDA Reviewing Safety Risks for GLP-1 Agents
January 23, 2023
- Label Revision Ordered for Acetaminophen to Add Drug-Induced Hypersensitivity Syndrome as ADR
January 19, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica on PAFSC Agenda for Feb. 1
January 19, 2023
- Chuikyo’s Drug Pricing Debate Slated to Begin in May after Expert Panel Proposal
January 19, 2023
- Emgality, Revestive, Veklury Brace for Price Cuts under CEA Scheme
January 19, 2023
- Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
- 5 Wholesalers to Be Slapped with 600 Million Yen Surcharges over Kyushu Bid-Rigging Case
January 18, 2023
- METI Aims at “1 or 2” Returns of Several 10s of Billions of Yen a Year from Biotech Ecosystem Program: Official
January 18, 2023
- HES Preparations Now Contraindicated in Patients with Severe Sepsis: Label Revisions
January 18, 2023
- Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
- MHLW Panel to Discuss Semaglutide for Obesity, Precedex, Entyvio SC on Jan. 27
January 17, 2023
- Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…